The specific aims are to determine the efficacy and safety of treatment with Ceftriaxone in people with amyotrophic lateral sclerosis (ALS). In a novel attempt to widen the search for potential therapeutic agents, an NINDS led cooperative group performed an in-vitro screening program of 1040 FDA approved drugs in assays relevant to various neurodegenerafive disorders. Several cephalosporins, including Ceftriaxone, were hits in ALS relevant assays including models suggesting increased expression of the astrocytic glutamate transporter, EAAT2 and protection from glutamate and superoxide dismutase mediated toxicity. Ceftriaxone has good CNS penetration and a long half-life. We propose a double-blind, placebo controlled clinical trial of Ceftriaxone in research participants with ALS. The study will determine optimal dosage, safety and efficacy, using a sequential, three STAGE, non- stop drug development design. The first two STAGES are complete. Sixty six subjects enrolled in STAGES 1 and 2 which included a placebo group and two groups receiving either 2 or 4 grams/day of Ceftriaxone. The initial objectives were met. Detailed pharmacokinetic studies showed that Ceftriaxone reached criterion levels in cerebrospinal fluid at both the 2 and 4 gram dosages. At the 4 gram dosage, levels remained above the target level long enough to permit drug holidays if clinically indicated. Both dosages met the prespecified tolerability criterion. Based on these data, an assessment was made that a safe dose can be given to ALS patients that will produce CSF levels reasonably expected to produce a biologic effect. The decision was made to proceed with the STAGE 3 efficacy portion of the study using a dosage of 4 grams daily. The study will be expanded to enroll a total of 600 research participants at centers in US and Canada. Subjects in STAGE 1 and 2 will be rolled over into this larger phase. All participants will continue in the study until the last subject completed 12 months of treatment;The co-primary outcome measures for the STAGE 3 efficacy are the difference in survival between treatment and placebo group at the end of study and the difference in rate of decline in function as measured by the ALS functional rating scales.

Public Health Relevance

Despite advances in understanding the cause of ALS, this remains an untreatable disease. The novel activities of cephalosporins provide a unique opportunity to evaluate a single agent aimed at several pathways important in ALS. Any compound that slews disease course will be immediately clinical important. A positive outcome will enhance our understanding of the underlying biology of motor neuron diseases.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZNS1-SRB-G (39))
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Oskarsson, Björn; Rocke, David M; Dengel, Karsten et al. (2016) Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. Neurology 86:1159-63
Raheja, Divisha; Stephens, Helen E; Lehman, Erik et al. (2016) Patient-reported problematic symptoms in an ALS treatment trial. Amyotroph Lateral Scler Frontotemporal Degener 17:198-205
Ratti, Elena; Berry, James D; Greenblatt, David J et al. (2015) Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. Toxicol Rep 2:1396-1403
Ramchandani, Ritesh; Finkelstein, Dianne M; Schoenfeld, David A (2015) A model-informed rank test for right-censored data with intermediate states. Stat Med 34:1454-66
Paganoni, Sabrina; Hyman, Theodore; Shui, Amy et al. (2015) Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. Muscle Nerve 52:339-43
Zhao, Yanli; Cudkowicz, Merit E; Shefner, Jeremy M et al. (2014) Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. J Clin Pharmacol 54:1180-7
Cudkowicz, Merit E; Titus, Sarah; Kearney, Marianne et al. (2014) Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13:1083-1091
Atassi, Nazem; Yerramilli-Rao, Padmaja; Szymonifka, Jackie et al. (2013) Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology 81:1350-5
Berry, James D; Shefner, Jeremy M; Conwit, Robin et al. (2013) Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS One 8:e61177
Berry, James D; Cudkowicz, Merit E (2011) New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig (Lond) 1:1375-1389

Showing the most recent 10 out of 13 publications